UCB Celltech Group has launched a new biotechnology base in Belgium, where the group will aim to improve its biological medicines.
The plant will produce cell culture-based therapeutic proteins that are dedicated to accelerating the availability of new drugs for severe diseases, with a focus on the research and clinical trial phases.
Roch Doliveux, chief executive of UCB, said: "By reinforcing its presence in biotechnology, UCB is equipping itself for the future. Today, 33 per cent of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB's current research and development pipeline."
The representative noted that the new plant will rapidly initiate clinical studies of antibody-based therapeutics.
News of this technology base follows the announcement that UCB's Neupro solution has been introduced to the US market.
The patch aims to treat Parkinson's Disease (PD) and Restless Legs Syndrome, while boosting motor function and activity of daily living among PD patients.
CSL are recruiters with a wealth of experience in the Clinical Research Jobs sector.